Canadian Journal of Infectious Diseases and Medical Microbiology (Jan 2022)

Analysis of the Influencing Factors of Immunological Nonresponders in Wuhan, China

  • Enze Lei,
  • Shuna Jin,
  • Wei Ni,
  • Manlin Feng,
  • Yanhe Luo,
  • Lianguo Ruan,
  • Mingzhong Xiao,
  • Jianzhong Liu

DOI
https://doi.org/10.1155/2022/5638396
Journal volume & issue
Vol. 2022

Abstract

Read online

Objective. CD4+ cell recovery is hampered in some human immunodeficiency virus (HIV)-infected patients, despite a successful highly active antiretroviral therapy (HAART) with suppressed viral replication. We investigated the factors that might have hindered the CD4+ cell recovery in these patients. Methods. In this retrospective study, we collected the data of all immune nonresponders (INRs) in Wuhan, China, until the end of 2020. A linear model was constructed based on the data from 220 patients with baseline and follow-up records. The response variables in this study were the CD4+ cell count increase. The predictor variables considered in this study were those factors likely to affect the CD4+ cell recovery. Results. Our findings revealed that the plasma HIV-1 viral load of all patients was suppressed and 87.3% patients’ CD4+ cells was increased after more than one year of the HAART treatment. In addition, their last follow-up showed a significant reduction in complications. In our results, the body mass index (BMI), number of months since HIV diagnosis to HAART start, and nonuse of co-trimoxazole were negatively correlated with the increase in CD4+ cells (P<0.05). However, there were positive associations between serum creatinine levels and CD4+ cell recovery (P<0.05). Further stratified analyses indicated that the associations between HAART replacement or creatinine usage and CD4+ cell growth were only observed in those participants with a BMI <18.5 (P<0.05). Conclusions. An early initiation of HAART and co-trimoxazole preventive therapy (CPT) can promote immune reconstitution. BMI and serum creatinine can serve as monitoring indicators of immune reconstitution prognosis after the HAART.